期刊文献+

利用患者骨髓瘤细胞建立NOD/SCID小鼠多发性骨髓瘤模型 被引量:1

Establishment of NOD/SCID-mouse model with multiple myeloma using myeloma cells from patients
下载PDF
导出
摘要 目的:探讨利用多发性骨髓瘤患者骨髓瘤细胞经植入兔骨建立 NOD/SCID 小鼠多发性骨髓瘤模型的可行性。方法分离取出新西兰白兔股骨与胫骨,清除肌肉、骨膜及软骨组织,沿中间轻柔截断;准备4~6周体质量约25~30 g的 NOD/SCID 小鼠,腹腔注射麻醉,将兔骨植入小鼠后背部,4周后检测兔骨植入成活情况。将分选的多发性骨髓瘤患者 CD38+/CD45-的浆细胞5×106经过免疫荧光标记后,由远侧端缓缓注入植入兔骨内。每周观察成瘤情况,采用 living-Imaging 方法检测小鼠体内浆细胞的生长情况,病理检测肿块性质。结果兔骨植入后4周成活,将分选的多发性骨髓瘤患者骨髓瘤细胞注入兔骨后,2周可见 NOD/SCID 小鼠荷瘤,8周后肿瘤体积大小约100 mm3。living-Imaging方法检测结果显示,在注射后2周可见兔骨局部有浆细胞浓聚,随着注射时间的延长,至注射后8周局部浆细胞浓聚现象更加明显(2.4×104 vs .1.5×105,P 〈0.05)。肿块病理活检可见大量浆细胞浸润,植入兔骨结构破坏,破骨细胞增多。结论NOD/SCID 小鼠兔骨植入可有效支持多发性骨髓瘤患者浆细胞局部注射,并建立 NOD/SCID 小鼠骨髓瘤模型,为骨髓瘤相关体内实验及临床药物筛选提供实验模型。 Objective To explore the feasibility of establishment of NOD/SCID-mouse model with multiple myeloma by using plasma cells from myeloma patients.Methods The femurs and tibias were removed from the New Zealand white rabbits;the muscles,periosteum and cartilage tissues were cleared.Then each bone was cut into two pieces gently along its middle.The NOD/SCID mice weighing 25 - 30 g (4 - 6 weeks)were anesthetized by intraperitoneal injection;rabbit bone was inserted into the right side of the mouse back and engraftment of the bones was allowed to take place after 4 weeks.The 5000 000 purified plasma cells which expressed CD38 +/CD45 - were immunofluorescence labeled and then injected slowly into the implanted rabbit bone through the distal end.The mice were observed weekly;the plasma cells growth in mice was screened by the living-imaging system and the tumor from the mice was determined by biopsy.Results The implanted rabbit bone survived after 4 weeks.The tumor in mice was observed 2 weeks after the purified myeloma cells were injected into the rabbit bone,and it reached 100 mm3 after 8 weeks.Results of the living-imaging system showed that the myeloma cells had uptake in the rabbit bone after 2 weeks of injection and this phenomenon was more pronounced after 8 weeks of injection (2.4×10 4 vs .1.5× 10 5 ,P 〈 0.05 ).The tumor infiltrated with numerous plasma cells and osteoclasts increased upon the biopsy. Conclusion Rabbit bone marrow implanted into NOD/SCID mice can effectively support local injection of plasma cells of multiple myeloma patients,and the NOD/SCID-mouse model of myeloma has been established.This model can be used to study in vivo experiments related to myeloma and clinical therapeutic approaches for this disease.
出处 《西安交通大学学报(医学版)》 CAS CSCD 北大核心 2015年第4期483-486,共4页 Journal of Xi’an Jiaotong University(Medical Sciences)
基金 河南省医学学术技术带头人出国培训计划项目(No.201201101)~~
关键词 多发性骨髓瘤 NOD/SCID 小鼠 模型 multiple myeloma NOD/SCID-mouse model
  • 相关文献

参考文献14

  • 1BIRD JM, OWEN RG, D'SA S, et al. Guidelines for the diag- nosis and management of multiple myeloma[J]. Br J Haema- tol, 2011, 154(1):32-75.
  • 2MOREAU P, RICHARDSON PG, CAVO M, et al. Harous- seau, Proteasome inhibitors in multiple myeloma: 10 years later [J]. Blood, 2012, 120(5) :947-959.
  • 3JOO C, COELHO I, COSTA C, et al. Efficacy and safety of lenalidomide in relapse/refractory multiple myeloma-Rcal life experience of a tertiary cancer eenter[J]. Ann Hematol, 2015, 94:97-105.
  • 4URASHIMA M, CHEN BP, CHEN S, et al. The development of a model for the homing of multiple myeloma cells to human bone marrow[J]. Blood, 1997, 90(2):754-765.
  • 5ANDERSON KC, ALSINA M, BENSINGER W, et al. Multi- ple myeloma, version 1. 2013[J]. J Natl Compr Canc Netw, 2013, 11(1) :11-18.
  • 6ZHU J, WANG M, CAO B, et al. Targeting the phosphati- dylinositol 3-kinase/AKT pathway for the treatment of multiple myeloma[J]. Curr Med Chem, 2014, 21(27):3173-3187.
  • 7DE LA PUENTE P, MUZ B, AZAB F, et al. Molecularly tar- geted therapies in multiple myeloma[J]. Leuk Res Treatment, 2014, 16.
  • 8YATA K, YACCOBY S. The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells[J]. Leukemia, 2004, 18 (11) :1891-1897.
  • 9YACCOBY S, BARLOGIE B, EPSTEIN J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biolo- gy and treatment of myeloma and its manifestations[J]. Blood, 1998, 92(8) :2908-2913.
  • 10李琰,杜恒飞,方洁,吕鸿雁,张金巧.去甲斑蝥素抗多发性骨髓瘤效应的体内实验研究[J].中华血液学杂志,2013,34(11):970-973. 被引量:4

二级参考文献13

  • 1杨漾,周晓曦,肖敏,洪振亚,龚泉,姜立军,周剑峰.Discovery of Chrysoeriol,a PI3K-AKT-mTOR Pathway Inhibitor with Potent Antitumor Activity against Human Multiple Myeloma Cells in vitro[J].Journal of Huazhong University of Science and Technology(Medical Sciences),2010,30(6):734-740. 被引量:8
  • 2范跃祖,赵泽明,陈春球,傅锦业.去甲斑蝥素对荷瘤裸鼠胆囊癌移植瘤增殖和凋亡的体内干预实验[J].中华普通外科杂志,2005,20(7):438-441. 被引量:10
  • 3Wang GS. Medical uses of mylabris in ancient China and recent studies. J Ethnopharmacol, 1989, 26:147-162.
  • 4McCluskey A, Ackland SP, Bowyer MC, et al. Cantharidin ana- logues: synthesis and evaluation of growth inhibition in a panel of selected tumour cell lines. Bioorg Chem, 2003, 31:68-79.
  • 5Du HF, Yu LJ, Meng YF, et al. Norcantharidin enhances bortezo- mib-antimyeloma activity in multiple myeloma cells in vitro and in nude mouse xenografts. Leuk Lymphoma, 2013, 54:607-618.
  • 6Sung B, Kunnumakkara AB, Sethi G, et al. Curcumin circum-vents chemoresistance in vitro and potentiates the effect of tha- lidomide and bortezomib against human multiple myeloma in nude mice model. Mol Cancer Ther, 2009, 8:959-970.
  • 7Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations acti- vate the noncanonical NF-kappaB pathway in multiple myelo- ma. Cancer Cell, 2007, 12:131-144.
  • 8Petros AM, Olejniczak ET, Fesik SW. Structural biology of the Bcl-2 family of proteins. Biochim Biophys Acta, 2004, 1644:83- 94.
  • 9Shin S, Sung B J, Cho YS, et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and-7. Biochemistry, 2001, 40:1117-1123.
  • 10宋晓宁,杜恒飞,于路佳,蒙艳凤,吕鸿雁,孙丽霞,孟建波,张金巧.去甲斑蝥素通过NF—κB/IκBα途径增强阿霉素的抗骨髓瘤效应[J].中华血液学杂志,2011,32(12):809-813. 被引量:9

共引文献4

同被引文献8

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部